ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Pulmonology
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)
Dermatology
In this ADVENT symposium at the 2024 EADV meeting, Professor Enno Schmidt discusses the pathophysiology of BP, focusing on autoimmunity and the role of type 2 inflammation.
Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation
Dermatology
In this video from the ADVENT symposium from Fall Clinical 2023, join Dr. Raj Chovatiya as he explores the contribution of type 2 inflammation to itch in AD, PN, and CSU.
The Journey to Diagnosis: Considerations For AD, PN, and CSU
Dermatology
In this symposium from Fall Clinical 2023, join Drs. James Q. Del Rosso and Raj Chovatiya as they explore the journey to diagnosis of type 2 inflammation in AD, PN, and CSU.
A Common Link: The Role of Type 2 Inflammation in the Clinical Presentation of AD, PN, and CSU
Dermatology
In this video from the ADVENT symposium at Fall Clinical 2023, join Dr. James Del Rosso as he explores the role of type 2 inflammation in the clinical presentation of AD, PN, and CSU.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.
